No Data
No Data
Clearmind Medicine Signs an Agreement to Source Manufacturers and Distributors for Its Alcohol Substitute Beverage Product
Vancouver, Canada, July 19, 2024 -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on discovery and development of novel
Top Midday Decliners
Charles Schwab's (SCHW) Q2 sales rose less than expected as net interest revenue, whose contribution to the top line is the largest, declined year over year.Shares fell 9% as intraday trading volume
Why Charles Schwab Shares Are Trading Lower By Over 7%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of The Charles Schwab Corporation (NYSE:SCHW) fell sharply during Tuesday's session following second-quarter results.Charles Schwab said adjusted net income declined 2% Y/Y to $1.465 billion.
Express News | Clearmind Medicine Inc - While Phase I/Iia Clinical Trial Was Already Approved in Israel, Clearance From FDA Will Allow Trial to Be Initiated in US.
Express News | Clearmind Medicine Announces FDA Clearance For IND Application Of MEAI-Based CMND-100 Oral Capsule; Phase I/IIa Clinical Trial For Alcohol Use Disorder To Proceed In The US; Trial Already Approved In Israel
Clearmind Medicine Obtains IND Approval From the FDA to Start the Phase I/IIa Clinical Trial With Its Innovative Treatment for Alcoholism
Vancouver, Canada, July 16, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on discovery and
No Data